The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.
 
David Ziegler
Consulting or Advisory Role - Accendatech; Alexion Pharmaceuticals; Amgen; AstraZeneca/Merck; Bayer; Day One Biopharmaceuticals; FivePhusion; Norgine; Novartis
Research Funding - Accendatech (Inst)
Travel, Accommodations, Expenses - Bayer
 
Jason Fangusaro
Consulting or Advisory Role - Fiore Biotherapeutics
Speakers' Bureau - Day One Biopharmaceuticals
 
Maria Tsoli
No Relationships to Disclose
 
Orazio Vittorio
No Relationships to Disclose
 
Tyler Shai-Hee
No Relationships to Disclose
 
Charles Minard
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Joel Reid
Consulting or Advisory Role - Elucida Oncology
 
Nawal Yahya
No Relationships to Disclose
 
Jennie Foster
Consulting or Advisory Role - US WorldMeds; Ymabs Therapeutics Inc
 
Elizabeth Fox
No Relationships to Disclose
 
Brenda Weigel
No Relationships to Disclose